Primary Assessment Method [Dose-Escalation Phase Ib Part]
Title	Efficacy in the phase Ib part
Number of patients screened	10
Number of patients enrolled	10
Number of patients evaluable for toxicity	10
Number of patients evaluated for efficacy	9
Evaluation method	RECIST 1.1
Response assessment, CR	0 (0%)
Response assessment, PR	2 (22.2%)
Response assessment, SD	1 (11.1%)
Response assessment, PD	6 (66.7%)
(Median) duration assessments, PFS	1.8 months (95% CI: 0.9-5.3)
(Median) duration assessments, TTP	1.8 months (95% CI: 0.9-5.3)
(Median) duration assessments, OS	4.7 months (95% CI: 2.6-21.4)
Response duration	1.5 months and 3.6 months, respectively
(Median) duration of treatment	1.3 months (range: 0.2-5.3 months)